Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. Fundamental Analysis
Amicus Therapeutics, Inc. (FOLD) shows moderate financial fundamentals with a PE ratio of -314.70, profit margin of -2.35%, and ROE of -6.84%. The company generates $0.6B in annual revenue with strong year-over-year growth of 32.29%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 22.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze FOLD's fundamental strength across five key dimensions:
Efficiency Score
WeakFOLD struggles to generate sufficient returns from assets.
Valuation Score
ExcellentFOLD trades at attractive valuation levels.
Growth Score
ExcellentFOLD delivers strong and consistent growth momentum.
Financial Health Score
ModerateFOLD shows balanced financial health with some risks.
Profitability Score
WeakFOLD struggles to sustain strong margins.
Key Financial Metrics
Is FOLD Expensive or Cheap?
P/E Ratio
FOLD trades at -314.70 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, FOLD's PEG of -5.01 indicates potential undervaluation.
Price to Book
The market values Amicus Therapeutics, Inc. at 19.20 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 71.66 times EBITDA. This signals the market has high growth expectations.
How Well Does FOLD Make Money?
Net Profit Margin
For every $100 in sales, Amicus Therapeutics, Inc. keeps $-2.35 as profit after all expenses.
Operating Margin
Core operations generate 5.48 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-6.84 in profit for every $100 of shareholder equity.
ROA
Amicus Therapeutics, Inc. generates $-1.62 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Amicus Therapeutics, Inc. generates limited operating cash flow of $13.20M, signaling weaker underlying cash strength.
Free Cash Flow
Amicus Therapeutics, Inc. generates weak or negative free cash flow of $9.86M, restricting financial flexibility.
FCF Per Share
Each share generates $0.03 in free cash annually.
FCF Yield
FOLD converts 0.22% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-314.70
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-5.01
vs 25 benchmark
P/B Ratio
Price to book value ratio
19.20
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.52
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.92
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.99
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.07
vs 25 benchmark
ROA
Return on assets percentage
-0.02
vs 25 benchmark
ROCE
Return on capital employed
0.05
vs 25 benchmark
How FOLD Stacks Against Its Sector Peers
| Metric | FOLD Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -314.70 | 29.43 | Better (Cheaper) |
| ROE | -6.84% | 800.00% | Weak |
| Net Margin | -2.35% | -20145.00% (disorted) | Weak |
| Debt/Equity | 1.92 | 0.30 | Weak (High Leverage) |
| Current Ratio | 2.99 | 4.64 | Strong Liquidity |
| ROA | -1.62% | -17936.00% (disorted) | Weak |
FOLD outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Amicus Therapeutics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
128.98%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
87.57%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
89.31%
Industry Style: Defensive, Growth, Innovation
High Growth